Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2022;33(2):185-95
Article Links
Course and Prognosis of AA Amyloidosis in Patients with Psoriatic Arthritis: Report of Three Cases from a Single Centre Cohort and Review of the Literature
Murat Bektaş, Nevzat Koca, Burak Ince, Yasemin Yalçınkaya, Bahar Artım Esen, M. Lale Öcal, Ahmet Gül, Murat Inanç
Authors Information

Division of Rheumatology, Department of Internal Medicine Istanbul Faculty of Medicine, Istanbul University, Çapa, Istanbul, Turkey

Keywords: psoriatic arthritis, AA amyloidosis, MEFV variants
References
  1. Eder L, Chandran V, Cook R, Gladman DD. The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. J Rheumatol 2017;44:286-91.
  2. Betteridge N, Boehncke WH, Bundy C, Gossec L, Gratacos J, Augustin M. Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol 2016;30:576-85.
  3. Hazenberg BP. Amyloidosis: a clinical overview. Rheum Dis Clin North Am 2013;39:323-45.
  4. Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: a systematic review. Amyloid 2020;27:1-12.
  5. Rosa RG, Tonietto TF, da Silva DB, Gutierres FA, Ascoli AM, Madeira LC, et al. Effectiveness and Safety of an Extended ICU Visitation Model for Delirium Prevention: A Before and After Study. Crit Care Med 2017;45:1660-7.
  6. Meneses CF, Egües CA, Uriarte M, Belzunegui J, Rezola M. Colchicine use in isolated renal AA amyloidosis. Reumatol Clin 2015;11:242-3.
  7. Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol 2019;29:363-6.
  8. Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24.
  9. Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. Medicine (Baltimore). 2017;96:e7859.
  10. Ryan JG, Dorman AM, O'Connell PG. AA amyloidosis in psoriatic arthritis. Ir J Med Sci. 2006;175:81-2.
  11. Klünemann H, Schneider J, Linke RP, Stey C, Schröder S. [Fatal generalized AA amyloidosis in mutilating psoriatic arthropathy]. Pathologe. 1994;15:366-71.
  12. Dinoia L, Lopalco G, Cantarini L, Gesualdo L, Rossini M, Iannone F. Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. Clin Exp Rheumatol 2017;35:170-1.
  13. Nossent JC, Gran JT. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Scand J Rheumatol 2009;38:251-5.
  14. Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012;142:w13580.
  15. Hazenberg BP, van Rijswijk MH. Where has secondary amyloid gone? Ann Rheum Dis. 2000;59:577-9.
  16. Tuglular S, Yalcinkaya F, Paydas S, Oner A, Utas C, Bozfakioglu S, et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 2002;17:2003-5.
  17. Erdogmus S, Kendi Celebi Z, Akturk S, Kumru G, Duman N, Ates K, et al. Profile of renal AA amyloidosis in older and younger individuals: a single-centre experience. Amyloid 2018;25:115-9.
  18. Tanabe H, Maki Y, Urabe S, Higuchi I, Obayashi K, Hokezu Y. Myopathy in a patient with systemic AA amyloidosis possibly induced by psoriasis vulgaris: An autopsy case. Muscle Nerve 2015;52:1113-7.
  19. Wittenberg GP, Oursler JR, Peters MS. Secondary amyloidosis complicating psoriasis. J Am Acad Dermatol 1995;32:465-8.
  20. Balzani A, Pagnotta A, Montesi G, Gravante G, Nicoli F, Cervelli V. A case of psoriasis with secondary amyloidosis, associated symbrachydactyly of the hand and a transverse deficiency of the foot. Eur Rev Med Pharmacol Sci 2012;16:983-5.
  21. Moise R, Asch L, Imbs JL. [PSORIATIC RHEUMATISM AND AMYLOIDOSIS]. Strasb Med 1965;16:245-53.
  22. Cefle A, Kamali S, Sayarlioglu M, Inanc M, Ocal L, Aral O, et al. A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. Rheumatol Int 2005;25:442-6.
  23. Dilşen N KM, Aral O, Öçal L. The Prevalence, Importance and Significance of Amyloidosis with Rheumatic Diseases in Turkey. Amyloid and Amyloidosis: Springer, Dordrecht; 1991. p. 870-3.
  24. Immonen K, Kauppi M, Hakala M. Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis. Scand J Rheumatol 2011;40(3):236-8.
  25. Rodríguez-Muguruza S, Martínez-Morillo M, Holgado S, Saenz-Sarda X, Mateo L, Tena X, et al. [Amyloidosis complicating spondyloarthropathies: Study of 15 cases]. Med Clin (Barc) 2015;145:327-31.
  26. Ece A, Çakmak E, Uluca Ü, Kelekçi S, Yolbaş I, Güneş A, et al. The MEFV mutations and their clinical correlations in children with familial Mediterranean fever in southeast Turkey. Rheumatol Int 2014;34:207-12.
  27. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84:1-11.
  28. Kasifoglu T, Calisir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol 2009;28:41-6.
  29. Cosan F, Ustek D, Oku B, Duymaz-Tozkir J, Cakiris A, Abaci N, et al. Association of familial Mediterranean fever-related MEFV variations with ankylosing spondylitis. Arthritis Rheum 2010;62:3232-6.
  30. Fiehn C, Andrassy K. Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Dis 2004;63:232.
  31. Canuel C, Krulik M, Mougeot-Martin M, Laplanche A, Gintzburger S, Genot JY, et al. [Psoriatic arthritis with renal amyloïdosis. A case-report. Review of the literature (author's transl)]. Sem Hop 1982;58:523-8.
  32. Atanasova P, Dimitrova D, Milkov V. [A patient with psoriatic arthritis and secondary amyloidosis]. Vutr Boles 1989;28:79-82.
  33. Ferguson A, Downie WW. Gastrointestinal amyloidosis in psoriatic arthritis. Ann Rheum Dis 1968;27:245-8.
  34. Willoughby CP, Bennett MK, Banerji A, Jewell DP. Gastrointestinal amyloidosis complicating psoriatic arthropathy. Postgrad Med J 1981;57:663-7.
  35. Berger PA. Amyloidosis--a complication of pustular psoriasis. Br Med J 1969;2:351-3.
  36. David M, Abraham D, Weinberger A, Feuerman EJ. Generalised pustular psoriasis, psoriatic arthritis and nephrotic syndrome associated with systemic amyloidosis. Dermatologica 1982;165:168-71.
  37. Ujfalussy I, Bely M, Koo E, Sesztak M. Systemic, secondary amyloidosis in a patient with psoriatic arthritis. Clin Exp Rheumatol 2001;19:225.
  38. Hakala M, Immonen K, Korpela M, Vasala M, Kauppi MJ. Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis. Ann Rheum Dis 2013;72:464-5.
  39. Sieper J, Poddubnyy D, Miossec P. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 2019;15:747-57.
  40. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 2015;373:2534-48.
  41. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 2015;373:1329-39.
  42. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700-12.
  43. Kofman T, Grimbert P, Canouï-Poitrine F, Zuber J, Garrigue V, Mousson C, et al. Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. Am J Transplant 2011;11:2423-31.
  44. Sarihan I, Caliskan Y, Mirioglu S, Ozluk Y, Senates B, Seyahi N, et al. Amyloid A Amyloidosis After Renal Transplantation: An Important Cause of Mortality. Transplantation 2020;104:1703-11.
  45. Keven K, Sengul S, Kutlay S, Ekmekci Y, Anadol E, Nergizoglu G, et al. Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: a single-center experience. Transplant Proc 2004;36:2632-4.
  46. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, Castro MC, Olive A, de Haro M, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552-6.
  47. Gertz MA. Secondary amyloidosis (AA). J Intern Med 1992;232:517-8.
  48. Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford) 2003;42:362-6.
  49. Qureshi MS, Sandle GI, Kelly JK, Fox H. Amyloidosis complicating psoriatic arthritis. Br Med J 1977;2:302.
  50. Tsuda S, Maeyama Y, Yamamoto N, Sasai Y, Yoshida K. Secondary amyloidosis complicating arthropathic psoriasis. Clin Exp Dermatol 1996;21:141-4.